Evidence-based expert consensus on the management of primary central nervous system lymphoma in China

作者：Tong Chen, Yuanbo Liu, Yang Wang, Qing Chang, Jinsong Wu, Zhiliang Wang, Daoying Geng, Jin‐Tai Yu, Yuan Li, Xiaoqiu Li, Hong Chen, Dongxiao Zhuang, Jianyong Li, Bin Wang, Tao Jiang, Lanting Lyu, Yuqin Song, Xiaoguang Qiu, Wenbin Li, Song Lin, Xinghu Zhang, Dehong Lu, Junqiang Lei, Yaolong Chen, Ying Mao · 发表于：Journal of Hematology & Oncology · 年份：2022 · DOI：10.1186/s13045-022-01356-7 · 被引用次数：73 · 研究领域：CNS Lymphoma Diagnosis and Treatment、Lymphoma Diagnosis and Treatment、Glioma Diagnosis and Treatment

Primary central nervous system lymphoma (PCNSL) is a type of central nervous system restricted non-Hodgkin lymphoma, whose histopathological diagnosis is majorly large B cell lymphoma. To provide specific, evidence-based recommendations for medical professionals and to promote more standardized, effective and safe treatment for patients with PCNSL, a panel of experts from the Chinese Neurosurgical Society of the Chinese Medical Association and the Society of Hematological Malignancies of the Chinese Anti-Cancer Association jointly developed an evidence-based consensus. After comprehensively searching literature and conducting systematic reviews, two rounds of Delphi were conducted to reach consensus on the recommendations as follows: The histopathological specimens of PCNSL patients should be obtained as safely and comprehensively as possible by multimodal tomography-guided biopsy or minimally invasive surgery. Corticosteroids should be withdrawn from, or not be administered to, patients with suspected PCNSL before biopsy if the patient's status permits. MRI (enhanced and DWI) should be performed for diagnosing and evaluating PCNSL patients where whole-body PET-CT be used at necessary time points. Mini-mental status examination can be used to assess cognitive function in the clinical management. Newly diagnosed PCNSL patients should be treated with combined high-dose methotrexate-based regimen and can be treated with a rituximab-inclusive regimen at induction therapy. Autolog...